BioCryst Pharma Issues Update Related to Peramivir, Says FDA Suggests Pre-NDA Meeting

BioCryst Pharmaceuticals, Inc. today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration that outlines a pathway by which BioCryst could file a New Drug Application seeking regulatory approval of intravenous peramivir.

http://www.benzinga.com/news/13/04/3459999/biocryst-pharma-issues-update-related-to-peramivir-says-fda-suggests-pre-nda-meet